COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis

J Am Soc Nephrol. 2022 Jan;33(1):33-37. doi: 10.1681/ASN.2021070936. Epub 2021 Oct 13.

Authors

Pablo Garcia¹, Shuchi Anand¹, Jialin Han¹, Maria E Montez-Rath¹, Sumi Sun², Tiffany Shang², Julie Parsonnet^{3

4}, Glenn M Chertow^{1

4}, Brigitte Schiller², Graham Abra²

Affiliations

¹ Department of Medicine (Nephrology), Stanford University, Stanford, California.
² Medical Clinical Affairs, Satellite Healthcare Inc., San Jose, California.
³ Department of Medicine (Infectious Diseases and Geographic Medicine), Stanford University, Stanford, California.
⁴ Department of Epidemiology and Population Health, Stanford University, Stanford, California.

No abstract available

Keywords: COVID-19; ESKD; SARS-CoV-2; dialysis; humoral; immunity; immunization; vaccine.

Publication types

Letter
Multicenter Study
Observational Study
Research Support, N.I.H., Extramural

MeSH terms

2019-nCoV Vaccine mRNA-1273 / administration & dosage
Ad26COVS1 / administration & dosage
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral / biosynthesis*
BNT162 Vaccine / administration & dosage
COVID-19 / immunology*
COVID-19 / prevention & control*
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / classification*
Cohort Studies
Female
Humans
Immunity, Humoral
Immunocompromised Host
Immunoglobulin G / biosynthesis
Immunoglobulin M / biosynthesis
Male
Middle Aged
Renal Dialysis / adverse effects*
SARS-CoV-2 / immunology
Seroconversion
Young Adult

Substances

Ad26COVS1
Antibodies, Viral
COVID-19 Vaccines
Immunoglobulin G
Immunoglobulin M
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine

Grants and funding